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P-glycoprotein and its role in drug-drug 
interactions
SUMMARY
Efflux transporters such as P-glycoprotein play an important role in drug transport in many 
organs. In the gut, P-glycoprotein pumps drugs back into the lumen, decreasing their absorption.
Drugs which induce P-glycoprotein, such as rifampicin, can reduce the bioavailability of some 
other drugs. Inhibitors of P-glycoprotein, such as verapamil, increase the bioavailability of 
susceptible drugs.
Many, but not all, of the drugs which are transported by P-glycoprotein are also metabolised by 
cytochrome P450 3A4. 
Important substrates of P-glycoprotein include calcium channel blockers, cyclosporin, dabigatran 
etexilate, digoxin, erythromycin, loperamide, protease inhibitors and tacrolimus. Predicting 
clinically important interactions is difficult because of interindividual differences in drug transport.
Drug absorption
The epithelial cell lining of the small intestine is 
not just a site for drug absorption, but also an 
important barrier to the absorption of xenobiotics. 
P-glycoprotein is found in the apical (luminal) 
membrane of the entire intestine from duodenum to 
rectum, with a high expression in the enterocytes of 
the small intestine. It reduces the oral availability of 
drugs that are its substrates.3,4 
Like the enzymes involved in drug metabolism, 
substrates of P-glycoprotein can potentially act as 
inhibitors or inducers of its function. Inhibition of 
P-glycoprotein can result in increased bioavailability 
of the susceptible drug. Induction of P-glycoprotein 
reduces the bioavailability.
Drug distribution
Once a drug has reached the systemic circulation, 
P-glycoprotein further limits penetration into a 
number of sensitive tissues. P-glycoprotein is also 
important for the blood-brain barrier as a defence 
against the penetration of toxins and drugs into the 
central nervous system.3
Drug elimination
P-glycoprotein has a modest role in drug elimination. 
It is expressed in the luminal membrane of proximal 
tubule cells in the kidneys. P-glycoprotein pumps 
drugs into the urine.   
Drug interactions
P-glycoprotein is an important mediator of drug-drug 
interactions.3 The pharmacokinetics of a drug may  
Introduction
P-glycoprotein is one of the drug transporters 
that determine the uptake and efflux of a range of 
drugs. This process affects their plasma and tissue 
concentrations and ultimately their final effects. 
P-glycoprotein functions as a transmembrane efflux 
pump, pumping its substrates from inside to outside 
the cell. Drugs which induce or inhibit P-glycoprotein 
can interact with other drugs handled by the pump. 
Pharmacology
P-glycoprotein was first described in tumour cells. 
These cells had over-expression of P-glycoprotein 
which reduced the access of cytotoxic drugs. As this 
made the tumours resistant to various anticancer 
drugs, P-glycoprotein was also known as multidrug 
resistance protein 1. P-glycoprotein is also expressed 
in a variety of normal, non-tumorous tissues with 
excretory functions (small intestine, liver and kidney)1 
and at blood-tissue barriers (blood-brain barrier, 
blood-testis barrier and placenta).2 
Along with the cytochrome P450 (CYP) family of 
enzymes, concomitant expression of P-glycoprotein is 
believed to be an important evolutionary adaptation 
against potentially toxic substances. As an efflux 
transporter it limits the bioavailability of orally 
administered drugs by pumping them back into the 
lumen. This promotes drug elimination into the bile 
and urine and protects a number of tissues such 
as the brain, testis, placenta and lymphocytes. The 
substrates for P-glycoprotein are a broad variety of 
structurally diverse compounds.2 
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P-glycoprotein and drug-drug interactions
medication loperamide is a potent opiate, but does 
not have opioid effects on the central nervous 
system at usual doses. This is because P-glycoprotein 
prevents transport across the blood-brain barrier. 
Concomitant administration of loperamide and a 
potent P-glycoprotein inhibitor, such as verapamil, 
may be associated with respiratory depression. This 
potentially dangerous central nervous system effect 
from such a widely used and easily accessible drug 
is of great interest. It raises safety concerns but 
suggests that inhibiting P-glycoprotein could be a 
novel strategy to overcome the blood-brain barrier to 
increase drug delivery to the brain.8  
Digoxin
Induction or inhibition of intestinal P-glycoprotein 
appears to be a major mechanism underlying drug 
interactions that lead to reduced or elevated digoxin 
concentrations. Rifampicin and St John’s wort induce 
P-glycoprotein and thereby decrease concentrations 
of digoxin.
HIV-1 protease inhibitors
The effective treatment of HIV may be hindered by 
P-glycoprotein located in cell membranes. Potential 
mechanisms include the following:
 • intestinal P-glycoprotein limits the absorption of 
HIV protease inhibitors
 • HIV protease inhibitors are good P-glycoprotein 
substrates,9 so this limits their transfer across the 
blood-brain barrier, which can contribute to viral 
persistence and reduced effectiveness 
 • P-glycoprotein is also expressed in CD4 cells, the 
major target of anti-HIV drugs.
Dabigatran
As dabigatran etexilate is a substrate of 
P-glycoprotein, there is potential for drug interactions 
involving drugs acting on P-glycoprotein. Inhibitors 
of P-glycoprotein such as ketoconazole, amiodarone, 
verapamil, ticagrelor and clarithromycin may increase 
the peak plasma concentrations of dabigatran, and 
subsequently lead to a significantly increased risk of 
severe haemorrhage.10
Conclusion
P-glycoprotein is an efflux transporter pump present 
in many organs and plays an important role in drug 
transport. Expression of P-glycoprotein can have 
important effects on drug absorption, distribution 
and elimination. Although interactions with drug 
transporters can be clinically insignificant, an 
awareness of potential transporter-related drug-drug  
be altered when co-administered with compounds 
which inhibit or induce P-glycoprotein.3,5,6 Inhibitors 
include clarithromycin, erythromycin, ritonavir 
and verapamil. Inducers include rifampicin and 
St John’s wort.
P-glycoprotein has a very wide substrate spectrum 
similar to CYP3A4. It is involved in the transport of 
drugs from different drug classes including:
 • antineoplastic drugs e.g. docetaxel, etoposide, 
vincristine
 • calcium channel blockers e.g. amlodipine
 • calcineurin inhibitors e.g. cyclosporin,  
tacrolimus
 • digoxin
 • macrolide antibiotics e.g. clarithromycin
 • protease inhibitors.
The substrates of P-glycoprotein can be further 
divided into drugs which are not metabolised 
in humans, such as digoxin, and those which 
are substrates of both P-glycoprotein and drug-
metabolising enzymes, particularly CYP3A4.2,3 As 
many P-glycoprotein substrates are also substrates 
of CYP3A4 and because P-glycoprotein inhibitors 
are also inhibitors of CYP3A4, many drug-drug 
interactions are related to inhibition or induction of 
both P-glycoprotein and CYP3A4. Drugs which are 
‘objects’ of such interactions include cyclosporin, 
tacrolimus and rivaroxaban.3 
Enterocytes, like hepatocytes, simultaneously express 
the major drug-metabolising enzyme CYP3A4 
and the efflux transporter P-glycoprotein.7 This 
creates a drug efflux–metabolism ‘alliance’, which 
increases the exposure of the drug to metabolism by 
CYP3A4 through repeated cycles of absorption and 
efflux.2 Modification of this active barrier function 
by concomitantly administered drugs contributes 
to altered absorption, increased interindividual 
differences in systemic drug concentrations and 
probably an increased risk of toxicity.4 
Accurate prediction of potential drug-drug 
interactions through P-glycoprotein is complicated 
by pronounced interindividual differences in 
bioavailability. This also affects drugs that are not 
metabolised in humans (fexofenadine, digoxin).2,4 A 
better knowledge of the role of genetics in transporter 
expression and function will contribute to a better 
understanding of interindividual and interethnic 
differences in drug disposition and effects.2
Loperamide 
P-glycoprotein is the most important drug transporter 
for reducing the entry of drugs into the central 
nervous system. The over-the-counter antidiarrhoeal 
SELF-TEST 
QUESTIONS
True or false? 
5. Inhibitors of 
P-glycoprotein increase 
the oral bioavailability 
of its substrates.
6. P-glycoprotein 
metabolises dabigatran.
Answers on page 143
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interactions in at-risk patient groups can help ensure 
the provision of safe and effective treatment. 
Conflict of interest: none declared
interactions is important. Central nervous system 
depression, undertreated HIV infection and 
transplant rejection are all possible outcomes if these 
interactions occur. Knowledge of these potential 
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New blurb for new drugs
First amended in Afatinib OF 16.05.14
New drugs
Del 19 (deletion in exon 19) and L858R (point mutation 
in exon 21). Afatinib is only approved for patients who 
have tumours with these mutations.
An open-label phase III comparative trial assessed the 
efficacy of afatinib (40 mg once a day) as a first-line 
treatment in 345 patients with an activating mutation 
in their EGFR gene. A subgroup of 308 patients had 
the Del 19 or L858R mutation. After a median of 
11 months, afatinib significantly prolonged median 
progression-free survival compared to chemotherapy 
(see Table). In the afatinib group, progression-free 
survival was 2.5 months longer in those with Del 19 
or L858R mutations. Afatinib did not significantly 
prolong overall survival compared to chemotherapy.1 
In a questionnaire about symptoms, the onset of 
cough (p=0.007) and dyspnoea (p=0.015) was 
significantly delayed with afatinib compared to 
chemotherapy. However, diarrhoea, dysphagia and 
sore mouth were reported to be worse.2 
A phase II trial in lung adenocarcinoma found that 
median progression-free survival was slightly longer 
for patients who received afatinib first-line compared 
Afatinib
Approved indication: non-small cell lung carcinoma
Giotrif (Boehringer Ingelheim)
10 mg, 30 mg, 40 mg and 50 mg film-coated tablets
Australian Medicines Handbook section 14.2.3
Like erlotinib (Aust Prescr 2006;29:53-5), gefitinib 
(Aust Prescr 2003;26:94-5) and crizotinib (Aust Prescr, 
published online 2014 Apr 16), afatinib is a tyrosine 
kinase inhibitor approved for advanced or metastatic 
non-small cell lung carcinoma. Afatinib irreversibly 
binds to the ErbB family of epidermal growth factor 
receptors − ErbB1 (epidermal growth factor receptor 
or EGFR), ErbB2 (human epidermal growth factor 
receptor 2 or HER2), ErbB3 and ErbB4. By blocking 
signalling from these molecules, afatinib slows down 
the growth and spread of tumour cells.
About 10% of Australian patients with non-small cell 
lung carcinoma have mutations in the EGFR gene. 
These are activating mutations which contribute to 
the malignant phenotype − the two most common are 
